Richard Pazdur, MD
The FDA has approved ado-trastuzumab emtansine (Kadcyla), also known as T-DM1, for HER2-positive metastatic breast cancer.
Verma S, Miles D, Gianni L. Updated overall survival results from EMILIA, a phase 3 study of T-DM1 (T-DM1) vs capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC). Paper presented at: 37th European Society for Medical Oncology Congress; September 28-October 2, 2012; Vienna, Austria. Abstract LBA12.
... to read the full story